Clinical significance of urinary inflammatory biomarkers in patients with IgA nephropathy

BMC Nephrology

Table 1 Baseline characteristics of the study population

	IgAN (n = 191)	Disease control (n = 53)	Normal control (n = 76)	P^d
Age, years	41.3 ± 15.3	46.4 ± 17.7^b	38.4 ± 15.4	0.018
Male, n (%)	99 (51.8)^a	33 (62.3)^b	19 (25.0)^c	< 0.0001
HTN, n (%)	80 (41.9)	20 (37.7)	0 (0.0)^c	< 0.0001
DM, n (%)	10 (5.2)^a	10 (18.9)^b	0 (0.0)^c	< 0.0001
BMI, kg/m²	23.9 ± 3.3	24.8 ± 3.2	22.9 ± 3.5^c	0.005
Albumin, g/dL	3.9 ± 0.6^a	2.9 ± 0.9^b	4.5 ± 0.2^c	< 0.0001
Creatinine, mg/dL	1.2 ± 0.9^a	0.9 ± 0.6^b	0.7 ± 0.1^c	< 0.0001
eGFR, ml/min/1.73 m²	83.0 ± 34.5^a	96.7 ± 33.6^b	109.6 ± 15.6^c	< 0.0001
C3, mg/dL	108.9 ± 20.7	116.6 ± 20.5	N/A	0.015
IgA, mg/dL	305.5 ± 103.9	242.5 ± 87.4	N/A	< 0.0001
Urine PCR, g/gCr	1.7 ± 2.1^a	5.4 ± 5.6^b	0.1 ± 0.1^c	< 0.0001

BMI, body mass index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HPF, high-power field; HTN, hypertension; IgAN, IgA nephropathy; PCR, protein–creatinine ratio; RBC, red blood cell
Different alphabets are significant differences between groups in the results of the Bonferroni post hoc analysis
^aP < 0.05, the other two respective groups vs. IgAN
^bP < 0.05, the other two respective groups vs. disease control
^cP < 0.05, the other two respective groups vs. normal control
^dP < 0.017 (0.05 divided by 3) was considered as significant difference

ISSN: 1471-2369